Modular Epitope Peptide Design for Uniform Antibody Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing immunotherapeutics face challenges in uniformly inducing the intended immune response and are costly to produce, lacking a systematic approach for peptide design that balances immunogenicity and synthesis ease.
Innovation Solution
A peptide unit comprising 23mer to 71mer peptides, including at least one Th epitope and one B-cell epitope, specifically designed to induce humoral immunity, with a focus on apolipoprotein B-100, and linked peptide units for easy synthesis and cost-effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing immunotherapeutics are used to induce immune response, then therapeutic effect is achieved, but production cost is high and immune response uniformity is poor
Solution Approach 1:
The peptide is segmented into functional modules including B-cell epitopes (20-30mer) and T-helper cell epitopes (15-25mer) connected by linkers. This modular segmentation enables standardized production while ensuring uniform immune response by separating antigen recognition functions into distinct, optimizable units.
Solution Approach 2:
The patent optimizes specific parameters including peptide length (20-30mer for B-cell epitopes), amino acid composition (incorporating immunogenic residues like hydrophobic and aromatic amino acids), and structural conformation (beta-turn structures). These parameter optimizations enhance immunogenicity while maintaining synthesis feasibility.
2Reliability
If peptide length is increased to improve immunogenicity, then antibody induction capability is enhanced, but synthesis complexity and cost increase
Solution Approach 1:
The peptide is divided into functional modules including B-cell epitopes (20-30mer) and T-helper cell epitopes (15-25mer) connected by linkers. This modular segmentation enables standardized production while ensuring uniform immune response by separating antigen recognition functions into distinct, optimizable units.
Solution Approach 2:
Only the essential immunogenic portions of proteins are extracted and synthesized as short peptides (20-30mer). By extracting and synthesizing only the critical epitope regions rather than full-length proteins, the patent achieves high immunogenicity with simplified synthesis processes.
3Reliability
If peptide structure is optimized for immunogenicity, then humoral immunity is enhanced, but synthesis ease is reduced
Solution Approach 1:
The patent optimizes specific parameters including peptide length (20-30mer for B-cell epitopes), amino acid composition (incorporating immunogenic residues like hydrophobic and aromatic amino acids), and structural conformation (beta-turn structures). These parameter optimizations enhance immunogenicity while maintaining synthesis feasibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide effectively induces targeted antibodies that bind to apolipoprotein B-100, demonstrating significant weight reduction and metabolic improvements in obesity models, indicating effective humoral immunity and economic feasibility.
Implementation Method 1
They differ from vaccines in that the antibody has not only a binding ability to the immunotherapeutic itself, but also a binding ability to a specific target in the body
Data Source
AI summary
Provided is a peptide provided herein includes at least one peptide unit, and the peptide unit may include at least one B-cell epitope, at least one Th epitope, and an appropriate number of auxiliary parts. The peptide unit is a portion designed to uniformly induce only the intended antibody while exhibiting a certain level of immunogenicity in the body of a subject. In addition, the peptide unit is designed with a relatively short length, and thus has the characteristics of easy synthesis and a low production cost. The peptide has properties suitable for use as an immunotherapeutic due to the characteristics of the peptide unit described above. In the present specification, the design principles of the peptide and the peptide unit are disclosed in detail.